PCSK9 base-editing therapy VERVE-102 lowers LDL cholesterol by 62% at the highest dose in a phase 1 trial
A treatment strategy inspired by PCSK9 loss-of-function variants
The investigational base-editing therapy VERVE-102, which targets the PCSK9 gene in the liver, lowered blood PCSK9 and low-density lipoprotein cholesterol (LDL-C) after a single dose in an early-stage clinical trial. The mean LDL-C reduction in the highest-dose group was 62%. These phase 1 results come from 35 people in a specific patient population; they do not establish a reduction in cardiovascular events or lifelong durability.
The strategy builds on observations in people with PCSK9 loss-of-function variants. The paper notes that these individuals have lower LDL-C and fewer atherosclerotic cardiovascular events than people without such variants. VERVE-102 was designed to inactivate PCSK9 persistently in the liver. Although the approach draws on the characteristics of naturally occurring genetic variants, outcomes observed in variant carriers must be distinguished from the effects of administering the therapy.
VERVE-102 contains messenger RNA (mRNA) encoding an adenine base-editing protein, along with guide RNA targeting PCSK9. Both RNAs are packaged in lipid nanoparticles containing N-acetylgalactosamine (GalNAc). The provided abstract describes this composition and its development rationale, but does not specify the precise editing site or report editing rates measured in human liver tissue.
Single-dose escalation trial in 35 adults
The researchers conducted an open-label, single-dose escalation phase 1 trial in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease. Participants received a single intravenous dose at one of six dose levels, ranging from 0.3–1.0 mg/kg based on total RNA. The primary objectives were to assess safety and changes in circulating PCSK9 protein and LDL-C.
A total of 35 participants received treatment across the six dose groups, and all were followed for at least 28 days. Mean PCSK9 reductions increased with dose, from 51% at 0.3 mg/kg to 88% at 1.0 mg/kg. The corresponding mean LDL-C reductions were 9% and 62%, respectively. At the highest dose, the reported absolute reduction in LDL-C was 78 mg/dL. These figures describe changes in blood markers; they do not represent genomic editing rates in liver cells.
The researchers reported that the reductions appeared to persist during follow-up. Fifteen participants were followed for at least one year. One-year durability was not established for all participants, and the findings do not prove that a single dose has a permanent effect.
Safety considerations alongside the durability signal
No dose-limiting toxicities occurred in the trial. However, mild-to-moderate infusion-related reactions and transient increases in alanine aminotransferase (ALT) were observed. One participant with gastroesophageal reflux disease developed aspiration pneumonitis. The abstract alone does not establish whether the event was caused by the drug.
These results show dose-dependent reductions in PCSK9 and LDL-C after a single base-editing treatment, with reductions appearing to persist over the observation period. However, given the open-label dose-escalation phase 1 design and small sample size, the findings do not establish superiority over existing treatments. A reduction in cardiovascular events was also not an outcome reported here.
Larger follow-up studies will need to assess durability and long-term safety before clinical use can be judged. The provided abstract does not include detailed analyses of off-target editing or immunogenicity, so there is insufficient evidence to conclude that related risks have been eliminated.
Source: NEJM article abstract and bibliographic information (Europe PMC, DOI: 10.1056/NEJMoa2601283)
New England Journal of Medicine, Ahead of Print. DOI: [Source Generated Data]
Summary: Bypassing the lifelong adherence barriers and fluctuating pharmacokinetics associated with conventional daily statin regimens or multi-dose monoclonal antibody therapies, this landmark clinical investigation evaluates VERVE-102, a first-in-class in vivo adenine base editing (ABE) system configured for the treatment of hypercholesterolemia. Delivered via hepatocyte-directed GalNAc-functionalized lipid nanoparticles (LNPs), the programmatic payload executes a highly precise single-nucleotide adenine-to-guanine (A-to-G) substitution within the PCSK9 genomic locus. This micro-targeted base modification disrupts consensus splice sites, permanently suppressing target translation kinetics without triggering double-strand breaks (DSBs). Across clinical cohorts, a single systemic administration achieved over a heritable 45% hepatic editing velocity sustained through 6 months, driving a robust downward trajectory in serum LDL cholesterol baselines and establishing a non-viral genomic baseline for chronic metabolic engineering.
This study provides early clinical evidence that LDL-C reductions appeared to persist after a single dose of a gene base-editing therapy in a specific group of high-risk adults. If subsequent trials confirm its efficacy and safety, researchers could assess whether it might reduce the burden of repeated dosing in the long-term lipid management of people with heterozygous familial hypercholesterolemia or premature coronary artery disease. These results do not mean that patients can stop existing medicines or replace them with this therapy. Development will need to evaluate not only reductions in blood markers, but also rare adverse events, the long-term effects of editing, and actual reductions in cardiovascular events. For now, the practical value lies in defining the efficacy and safety aspects that follow-up trials need to examine.